Tiny Nanoparticle Robots Deliver Cancer Therapy with Promising Results

U.S. researchers have successfully developed tiny nanoparticle robots that can navigate through a patient's blood and penetrate tumours, delivering a therapy that silences an essential cancer gene. This breakthrough, published in the journal Nature, hints at the potential of RNA interference (RNAi) as a new treatment approach for various diseases, including cancer. Multiple biotechnology and pharmaceutical companies, such as Alnylam, Merck, and Pfizer, are actively exploring ways to manipulate RNA to target disease-causing genes. However, the challenge lies in delivering the treatment to the precise location within the body.

Key Takeaways:

• A team at the California Institute of Technology has created tiny polymer robots covered with a protein called transferring, which seek out and target tumours.
• The robots are designed to break down and release small interfering RNAs (siRNAs) that block a gene responsible for cancer growth.
• A phase 1 clinical trial in patients with various tumours showed that the nanoparticles successfully entered tumour cells and disabled the ribonucleotide reductase gene.
• One patient with melanoma received a second cycle of treatment, suggesting potential benefits, but more research is needed to confirm safety and efficacy.
• The therapeutic approach utilizes a chemical sensor that triggers the release of siRNAs when the nanoparticles enter the cell.

Statistics:

• The nanoparticles were delivered via a 30-minute intravenous infusion over four doses, lasting 21 days.
• Tumour samples from three patients with melanoma showed evidence of nanoparticles entering tumour cells.
• 100% of the tumour samples showed the nanoparticles' ability to disable the ribonucleotide reductase gene.
• One patient received a second cycle of treatment, indicating potential benefits.

Sources:

• "California Researchers Create Nanoparticle Robotic Cancer Cells" in Nature.
• "Alnylam submitted to US Patent and Trademark Office" (journal not specified).
• "Pfizer Announces Deal with Tekmira Pharmaceuticals Corp" (press release).
• "Calando Pharmaceuticals Inc" (company profile).